Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study
<b>Background/Objectives</b>: Early-onset colorectal cancer (EOCRC) is more frequently characterized by poorly differentiated, aggressive tumors, often diagnosed at advanced stages, and associated with worse prognoses. Despite these differences, current treatment guidelines do not distin...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/54 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589017732874240 |
|---|---|
| author | Lana Jajac Brucic Vesna Bisof Majana Soce Marko Skelin Ivan Krecak Andjela Nadinic Branka Vrbicic Zivana Puljiz Suzana Hancic Slavko Gasparov |
| author_facet | Lana Jajac Brucic Vesna Bisof Majana Soce Marko Skelin Ivan Krecak Andjela Nadinic Branka Vrbicic Zivana Puljiz Suzana Hancic Slavko Gasparov |
| author_sort | Lana Jajac Brucic |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Early-onset colorectal cancer (EOCRC) is more frequently characterized by poorly differentiated, aggressive tumors, often diagnosed at advanced stages, and associated with worse prognoses. Despite these differences, current treatment guidelines do not distinguish between EOCRC and late-onset colorectal cancer (LOCRC). Elevated expression of polo-like kinase 1 (PLK-1) has been linked to advanced disease stages and poorer treatment outcomes, including resistance to both chemotherapy and radiotherapy. However, data on PLK-1 expression in EOCRC compared to LOCRC remain limited. <b>Methods</b>: Patients with sporadic CRC, aged >18 years, were included in this study. We categorized the patients into two groups: patients younger than 50 years, and those aged 50 years or older. Immunohistochemical staining was performed to assess PLK-1 expression. The aim of this study was to assess PLK-1 expression considering the age of the patients and its effects on overall survival (OS) and progression-free survival (PFS). <b>Results</b>: A total of 146 patients with metastatic colorectal cancer (mCRC) were included in this retrospective two-center study. Patients with low PLK-1 expression were older than patients with high PLK-1 expression (64 (49–71) years vs. 49 (42–67) years, <i>p</i> = 0.016). Multiple logistic regression confirmed that age is a significant predictor of PLK-1 expression, independent of the covariates (<i>p</i> = 0.036). The Kaplan–Meier analysis revealed no significant association between PLK-1 expression and PFS (<i>p</i> = 0.397) or OS (<i>p</i> = 0.448). Accordingly, Cox proportional hazards regression analysis showed no significant association between PLK-1 expression and OS (HR 1.20, 95% CI 0.73–1.96, <i>p</i> = 0.598) or PFS (HR 0.85, 95% CI 0.51–1.43, <i>p</i> = 0.611) when covariates were taken into account. Finally, no significant differences in PFS (<i>p</i> = 0.423) or OS (<i>p</i> = 0.104) were found between the age groups of interest. <b>Conclusions</b>: PLK-1 expression was not associated with survival or progression in EOCRC and LOCRC patients. Further research on these combinations is necessary, as well as the discovery of new potential targets for targeted therapy and the mechanisms of synergistic effects in tumors with PLK-1 overexpression. |
| format | Article |
| id | doaj-art-f3b8a1e869a14c7b93bf0f162519c465 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-f3b8a1e869a14c7b93bf0f162519c4652025-01-24T13:23:51ZengMDPI AGBiomedicines2227-90592024-12-011315410.3390/biomedicines13010054Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center StudyLana Jajac Brucic0Vesna Bisof1Majana Soce2Marko Skelin3Ivan Krecak4Andjela Nadinic5Branka Vrbicic6Zivana Puljiz7Suzana Hancic8Slavko Gasparov9Department of Hematology, Oncology, Allergology and Clinical Immunology, General Hospital of Sibenik-Knin County, 22000 Sibenik, CroatiaDepartment of Oncology, University Hospital Center Zagreb, 10000 Zagreb, CroatiaDepartment of Oncology, University Hospital Center Zagreb, 10000 Zagreb, CroatiaPharmacy Department, General Hospital of Sibenik-Knin County, 22000 Sibenik, CroatiaDepartment of Hematology, Oncology, Allergology and Clinical Immunology, General Hospital of Sibenik-Knin County, 22000 Sibenik, CroatiaDepartment of Hematology, Oncology, Allergology and Clinical Immunology, General Hospital of Sibenik-Knin County, 22000 Sibenik, CroatiaDepartment of Pathology and Cytology, General Hospital of Sibenik-Knin County, 22000 Sibenik, CroatiaDepartment of Biochemical Engineering, Faculty of Food Technology and Biotechnology Zagreb, 10000 Zagreb, CroatiaInstitute of Clinical Pathology and Cytology, Merkur University Hospital, 10000 Zagreb, CroatiaInstitute of Clinical Pathology and Cytology, Merkur University Hospital, 10000 Zagreb, Croatia<b>Background/Objectives</b>: Early-onset colorectal cancer (EOCRC) is more frequently characterized by poorly differentiated, aggressive tumors, often diagnosed at advanced stages, and associated with worse prognoses. Despite these differences, current treatment guidelines do not distinguish between EOCRC and late-onset colorectal cancer (LOCRC). Elevated expression of polo-like kinase 1 (PLK-1) has been linked to advanced disease stages and poorer treatment outcomes, including resistance to both chemotherapy and radiotherapy. However, data on PLK-1 expression in EOCRC compared to LOCRC remain limited. <b>Methods</b>: Patients with sporadic CRC, aged >18 years, were included in this study. We categorized the patients into two groups: patients younger than 50 years, and those aged 50 years or older. Immunohistochemical staining was performed to assess PLK-1 expression. The aim of this study was to assess PLK-1 expression considering the age of the patients and its effects on overall survival (OS) and progression-free survival (PFS). <b>Results</b>: A total of 146 patients with metastatic colorectal cancer (mCRC) were included in this retrospective two-center study. Patients with low PLK-1 expression were older than patients with high PLK-1 expression (64 (49–71) years vs. 49 (42–67) years, <i>p</i> = 0.016). Multiple logistic regression confirmed that age is a significant predictor of PLK-1 expression, independent of the covariates (<i>p</i> = 0.036). The Kaplan–Meier analysis revealed no significant association between PLK-1 expression and PFS (<i>p</i> = 0.397) or OS (<i>p</i> = 0.448). Accordingly, Cox proportional hazards regression analysis showed no significant association between PLK-1 expression and OS (HR 1.20, 95% CI 0.73–1.96, <i>p</i> = 0.598) or PFS (HR 0.85, 95% CI 0.51–1.43, <i>p</i> = 0.611) when covariates were taken into account. Finally, no significant differences in PFS (<i>p</i> = 0.423) or OS (<i>p</i> = 0.104) were found between the age groups of interest. <b>Conclusions</b>: PLK-1 expression was not associated with survival or progression in EOCRC and LOCRC patients. Further research on these combinations is necessary, as well as the discovery of new potential targets for targeted therapy and the mechanisms of synergistic effects in tumors with PLK-1 overexpression.https://www.mdpi.com/2227-9059/13/1/54colorectal cancerpolo-like kinase 1metastasistargeted therapy |
| spellingShingle | Lana Jajac Brucic Vesna Bisof Majana Soce Marko Skelin Ivan Krecak Andjela Nadinic Branka Vrbicic Zivana Puljiz Suzana Hancic Slavko Gasparov Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study Biomedicines colorectal cancer polo-like kinase 1 metastasis targeted therapy |
| title | Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study |
| title_full | Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study |
| title_fullStr | Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study |
| title_full_unstemmed | Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study |
| title_short | Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study |
| title_sort | polo like kinase 1 expression as a biomarker in colorectal cancer a retrospective two center study |
| topic | colorectal cancer polo-like kinase 1 metastasis targeted therapy |
| url | https://www.mdpi.com/2227-9059/13/1/54 |
| work_keys_str_mv | AT lanajajacbrucic pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT vesnabisof pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT majanasoce pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT markoskelin pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT ivankrecak pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT andjelanadinic pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT brankavrbicic pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT zivanapuljiz pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT suzanahancic pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy AT slavkogasparov pololikekinase1expressionasabiomarkerincolorectalcanceraretrospectivetwocenterstudy |